Australian biotech company Ena Respiratory said that its nasal spray significantly mitigated Covid-19 virus levels in the nose and throat in a study on animals.

The treatment could potentially enhance the human immune system against common colds and flu.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

INNA-051 is a synthetic small molecule self-administered via a nasal spray once or twice a week, used alone or along with vaccine programmes for Covid-19.

Researchers performed the study, published on biomedical prepublication research site bioRxiv, on ferrets. Led by Public Health England (PHE) scientists, the study showed that INNA-051 decreased viral replication by up to 96%.

On obtaining positive toxicity study results and regulatory approval, Ena Respiratory expects to progress the nasal spray into human trials within four months.

Ena Respiratory managing director Christophe Demaison said: “By boosting the natural immune response of the ferrets with our treatment, we’ve seen a rapid eradication of the virus.

“If humans respond in a similar way, the benefits of treatment are two-fold. Individuals exposed to the virus would most likely rapidly eliminate it, with the treatment ensuring that the disease does not progress beyond mild symptoms.”

The company secured approximately $8.24m (A$11.7m) in a funding round led by the Brandon Capital-managed Medical Research Commercialisation Fund (MRCF).

The Australian Government, AustralianSuper, HESTA, Hostplus, StatewideSuper, biotech firm CSL and Uniseed also contributed to the funding.

Uniseed CEO Dr Peter Devine noted: “These are very exciting results and demonstrate the potential clinical utility of the Ena drug in the treatment of Covid-19 which will likely require multiple treatment approaches.

“It also underlines the value of facilitating early-stage commercialisation of research, which can go on to create a global impact.”

The company plans to raise additional funds to speed-up the nasal spray’s clinical development and distribution worldwide.